[Comparison on the effects of clopidogrel, statins combination in treating coronary artery disease among the elderly patients: a retrospective cohort study].

First Geriatric Cardiology Division, Department of Geriatric Hematology, Chines PLA General Hospital, Beijing, China.
Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi 03/2012; 33(3):337-41.
Source: PubMed


To compare the effects of clopidogrel with or without combined with CYP3A4-metabolized statin in treating coronary artery disease (CAD) among the elderly patients.
The study cohort was defined as all patients were over 60 years of age and hospitalized for CAD who were prescribed clopidogrel between January 2000 and February 2011. A total of 1021 patients were enrolled, with 178 of them prescribed clopidogrel and 843 patients were administrated clopidogrel combined with statins (CYP3A4-metabolized statins 636 and non CYP3A4-metabolized statins 207). The primary endpoint was all cause of death and the second endpoint were non-fatal myocardial infarction (MI), but hospitalized for unstable angina, stroke, transient ischemic attack, or repeated revascularization (PCI or coronary artery bypass graft).
Among the clopidogrel group and the clopidogrel plus statins group, the incidence density of death was 6.86/1000 and 3.18/1000 respectively, with crude RR as 2.15 (95%CI: 1.39-3.33) and statistically significant (χ2=3.53, P<0.01). The incidence density of composite thromboembolic events did not show statistical significance (P>0.05). The two groups were 1:1 matched, after propensity score matching, clopidogrel coadministrated with statins group showed significant decrease in all cause of death, with RR as 0.42 (95%CI: 0.19-0.93), χ2=7.23, P<0.01. No significant difference was observed in deaths or composite thromboembolic events between statins via different cytochrome P450 pathways.
Clopidogrel with statin could reduce the mortality of elderly CAD patients compared with clopidogrel without statin. The result did not show statistical significance between CYP3A4-metabolized statins or non CYP3A4-metabolized statins regarding the mortality or composite endpoint events.

8 Reads